Cathleen June Park
Biography
Cathleen June Park, M.D., is a Health Sciences Assistant Clinical Professor in the Division of Hematology/Oncology at the Chao Family Comprehensive Cancer Center at the University of California, Irvine. She completed her M.D. at the University of Cincinnati College of Medicine, followed by an Internal Medicine residency at the University of Cincinnati, an Experimental Therapeutics Fellowship at the University of Cincinnati Cancer Center, and a Hematology & Oncology Fellowship at the University of California Davis Cancer Center, where she served as Chief Fellow. Park is board certified in both Medical Oncology and Internal Medicine by the American Board of Internal Medicine.
Park's research focuses on thoracic oncology, particularly non-small cell lung cancer (NSCLC) with targetable mutations such as ALK and EGFR. She has contributed to the development of clinical trial protocols, including a phase I study evaluating receptor-mediated bispecific nano-immunoengineers as a strategy to overcome immunotherapy resistance, and a pilot trial examining locally ablative therapies for patients with oligo-progressive solid tumors. She participated in the ASCO/AACR Workshop on Methods in Clinical Cancer Research in 2023, where she developed a phase I protocol for advanced solid tumors.
Park has authored multiple publications in thoracic oncology and has been an active contributor to the COVID-19 and Cancer Consortium, examining outcomes and disparities in cancer patients during the pandemic. Her recent work includes commentary on ALK tyrosine kinase inhibitors, neoadjuvant osimertinib in resectable EGFR-positive NSCLC, and deuterated targeted therapies. She has presented research at national and international conferences, including ASCO and ESMO meetings, on topics ranging from dose intensity reporting in clinical trials to precision neoadjuvant therapy in resectable NSCLC.
Return to topEducation
- B.S. in Psychology, University of California San Diego, 2010
- M.S. in Physiology, University of Cincinnati College of Medicine, 2013
- M.D., University of Cincinnati College of Medicine, 2017
Areas of Expertise
- Thoracic Oncology
- Tyrosine Kinase Inhibitor Therapy
- COVID-19 Cancer Outcomes
- Carcinoma Unknown Primary
- Neoadjuvant Osimertinib Treatment
- Deuterated Drug Development
- Bispecific Nano-Immunoengager Therapy
Recent Publications
- Park CJ, Saw SPL, “Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?” (opens in new tab), Journal of Thoracic Oncology, vol. 20, no. 5, pp. 542-545, 2025.
- Park CJ, Li MS, Ou SI, “Old Wine in New Bottles? Deuterium Switch (Replacing Hydrogen With Deuterium) Comes to Thoracic Oncology as Deuterated Lorlatinib (Deulorlatinib, TGRX-326) and Deuterated Osimertinib (Asandeutertinib, TY-9591) in ALK+ NSCLC and EGFR+ NSCLC, Respectively” (opens in new tab), Journal of Thoracic Oncology, vol. 20, no. 6, pp. 708-713, 2025.
- Brazel D., Park C.J., Nagasaka M., “The development of Zongertinib for HER2-mutant NSCLC” (opens in new tab), Critical Reviews in Oncology Hematology, vol. 215, 2025.
- Arter Z.L., Park C., Deng L., “MET Tyrosine Kinase Domain Mutations in NSCLC: Expanding the Landscape of Acquired Resistance in Oncogene-Driven Tumors” (opens in new tab), Journal of Thoracic Oncology, vol. 20, pp. 998-1000, 2025.
- Ou S.-H.I., Park C.J., Arter Z.L., Nagasaka M., “Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib” (opens in new tab), Lung Cancer Targets and Therapy, vol. 16, pp. 139-145, 2025.
- Lee A.T.M., Park C.J., Arter Z.L., Nagasaka M., Ou S.-H.I., “Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report” (opens in new tab), Lung Cancer Targets and Therapy, vol. 16, pp. 199-203, 2025.
- Park C, Lee A, Ou SH, “ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer?” (opens in new tab), Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, vol. 0, pp. 625-628, 2024.
- Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, et al., “Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer” (opens in new tab), JAMA Netw Open, vol. 5, no. 3, pp. e224304, 2022.
- Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, et al., “Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study” (opens in new tab), Cancers (Basel), vol. 14, no. 17, pp. 4334, 2022.
- Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, et al., “Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19” (opens in new tab), JAMA Oncol, vol. 7, no. 8, pp. 1167-75, 2021.
- COVID-19 and Cancer Consortium, “A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance” (opens in new tab), Cancer Cell, vol. 38, no. 6, pp. 761-766, 2020.
- Sherman KE, Ke R, Rouster SD, Abdel-Hameed EA, Park C, Palascak J, Perelson AS, “Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs” (opens in new tab), Haemophilia, vol. 22, no. 4, pp. 543-8, 2016.
- RamachandraRao SP, Matthias MA, Kokoy-Mondragon C, Aghania E, Park C, Kong C, Ishaya M, Madrigal A, Horng J, Khoshaba R, Bounkhoun A, Basilico F, De Palma A, Agresta AM, Awdishu L, Naviaux RK, Vinetz JM, Mauri P, “Proteomic analysis of urine exosomes reveals renal tubule response to leptospiral colonization in experimentally infected rats” (opens in new tab), PLoS Negl Trop Dis, vol. 9, no. 3, pp. e0003640, 2015.
This profile was created with the help of AI.
Last updated on 2/17/2026.